MANGALAM2023-07-012023-09-30 MANGALAM2023-07-012023-09-30 MANGALAM2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member MANGALAM2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member MANGALAM2023-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532637 MANGALAM NOTLISTED Mangalam Drugs And Organics Limited Equity 2023-04-01 2024-03-31 2023-11-08 2023-11-01 INR Lakhs Half yearly 16:00:00 19:50:00 2023-11-08 2023-11-08 true Cash Flow Indirect Not applicable Single segment Manufacturing of Bulk Drugs 2023-07-01 2023-09-30 Unaudited Consolidated 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 158282000.00 10 0.00 0.00 0.00 0.00 0.00 0.00 1. The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter. 2. The above Audited financial results of the Company for the year ended have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company at their meeting held on November 8, 2023. 3. The Company's business activity falls within a single reportable Business Segment Viz. “Manufacturing of Bulk Drugs”. 4. The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation. 5. Consolidated results includes results of Mangalam Laboratories Private Limited, subsidiary for the purpose of Consolidated results. 6. As on september 30, 2023, Mangalam Drugs and Organics Limited has acquired 3010 equity shares of Rs. 100/- each. Hence Mangalam Laboratories Private Limited became wholly owned subsidairy of Managalam Drugs and Organics Limited. The wholly owned subsidiary is not a material subsidiary of the Mangalam Drugs and Organics Limited. 7. Since the Mangalam Laboratories Private Limited has become subsidiary as on September 30, 2023 the figures for consolidation for the quarter ended September 30, 2023 and Balance Sheet & Cash flow as on March 31, 2023 is not applicable. Single segment 2023-04-01 2023-09-30 Unaudited Consolidated 1690236000.00 695000.00 1690931000.00 1265574000.00 6443000.00 -106120000.00 189936000.00 66567000.00 71580000.00 347387000.00 1841367000.00 -150436000.00 0.00 -150436000.00 0.00 -19439000.00 -19439000.00 0.00 -130997000.00 0.00 0.00 0.00 0.00 -130997000.00 624000.00 -130373000.00 0.00 0.00 0.00 0.00 158282000.00 10 -8.28 -8.28 0.00 0.00 -8.28 -8.28 Other Expenses 0.00 Other Expenses 347387000.00 0.00 1058925000.00 0.00 0.00 0.00 416599000.00 35879000.00 0.00 0.00 43000.00 0.00 0.00 13502000.00 13545000.00 0.00 1524948000.00 1405273000.00 0.00 289877000.00 56547000.00 76000.00 168314000.00 361779000.00 876593000.00 0.00 2281866000.00 0.00 0.00 3806814000.00 158282000.00 1165585000.00 1323867000.00 1323867000.00 178073000.00 0.00 213842000.00 391915000.00 0.00 0.00 0.00 0.00 391915000.00 576557000.00 1047426000.00 124717000.00 1748700000.00 316827000.00 25505000.00 0.00 0.00 2091032000.00 0.00 0.00 2482947000.00 3806814000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -150436000.00 0.00 0.00 0.00 0.00 0.00 -150436000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -150436000.00 0.00 -150436000.00 0.00 -150436000.00 0.00 624000.00 0.00 0.00 0.00 0.00